• NuCana highlighted cash and cash equivalents of about USD 28.4 million as of March 31, 2026.
• Cash runway projected into 2029.
• Lead program NUC-7738 advanced in the NuTide:701 study across monotherapy and pembrolizumab combination cohorts.
• Monotherapy dataset showed a 41% disease control rate in efficacy-evaluable patients, with no Grade 4 toxicities and low Grade 3 rates.
• Combination dose-confirmation cohort (n=12) reported tumor reductions of 55% and 32%, including an ongoing complete metabolic response; one Grade 4 transaminitis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NuCana plc published the original content used to generate this news brief on July 01, 2026, and is solely responsible for the information contained therein.